Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Open Access
- 1 October 2013
- journal article
- review article
- Published by Elsevier in The American Journal of Pathology
- Vol. 183 (4) , 1064-1074
- https://doi.org/10.1016/j.ajpath.2013.05.033
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer, 2012
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- The Life History of 21 Breast CancersCell, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 StudyClinical Cancer Research, 2011
- Deconstructing the molecular portraits of breast cancerPublished by Wiley ,2010
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesPublished by Elsevier ,2006
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006